Shanghai Haohai Biological Technology Co., Ltd. announced that Mr. Chen Huabin ("Mr. Chen"), Mr. Shen Hongbo ("Mr. Shen") and Mr. Zhu Qin ("Mr. Zhu") have tendered the resignation as independent non-executive Directors of the Company ("INED(s)") as well as their respective related positions of Board Committees due to their six-year term of re-election as INED(s). Mr. Wong Kwan Kit ("Mr. Wong") has tendered his resignation as an INED as well as the position of the Board Committees due to his personal work commitments. On 14 May 2020, the Board has resolved to propose the appointment of Ms. Li Yingqi, Mr. Zhao Lei, Mr. Su Zhi, Mr. Jiang Zhihong and Mr. Yang Yushe as INEDs. The resignation of Mr. Chen, Mr. Shen, Mr. Zhu and Mr. Wong will take effect after, inter alia, the resolutions in relation to the proposed appointment of the new INEDs to be passed on the annual general meeting of the Company to be convened on 29 June 2020 (the "AGM"). The appointment of the new INEDs will take effect from AGM date.
Shanghai Haohai Biological Technology Co., Ltd. is a China-based company principally engaged in biological technology-related businesses. The businesses of the Company include the manufacture and sales of biological and medical hyaluronate, the research and development of biological engineering and pharmaceutical products and the provision of related services. Its products include orthopedics products, medical aesthetics and wound care products, ophthalmology products and anti-adhesion and hemostasis products, among others. Orthopedics products include sodium hyaluronate injection, medical chitosan and medical sodium hyaluronate gel. Medical aesthetics and wound care products include recombinant human epidermal growth factor (rhEGF), among others. Ophthalmology products include ophthalmic viscoelastic devices and lubricant eye drops. Anti-adhesion and hemostasis products include medical collagen sponges, among others. The Company mainly operates businesses in Mainland China.